Bone Solutions said today that it entered into a private label licensing agreement with Onkos Surgical for its OsteoCrete bone void-filling technology.
Colleyville, Texas-based BSI’s OsteoCrete is an FDA 510(k)-cleared magnesium-based injectable, moldable solution designed to attaching ligaments and tendons to bone and bone to bone. Parsippany, N.J.-based Onkos Surgical intends to market OsteoCrete under the GenVie brand.
Earlier this month BSI agreed to a private label distribution deal with WishBone Medical, granting WishBone worldwide rights to OsteoCrete for pediatric indications, reporting more than 600 cases implanting OsteoCrete this year.